IDL Diagnostics AB (publ), formerly AroCell AB (publ), is a Sweden-based diagnostic Company engaged in the biotechnology and medical diagnostics industry. The Company focuses on research, development, manufacturing, and commercialization of diagnostic and medical technology products. The Company has a broad product portfolio of In Vitro Diagnostics (IVD) tests that deliver clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. IDL Diagnostics AB (publ) develops tests that are clinically useful and economically viable. The Company provides rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, as well as easy to perform.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-05 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
20/10/26	SEK 0.3480	-1.97%	3,218
19/10/26	SEK 0.3550	+2.90%	43,787
16/10/26	SEK 0.3450	+1.47%	163,524
15/10/26	SEK 0.3400	-2.86%	61,245
13/10/26	SEK 0.3500	-2.78%	152,380

Delayed Quote Nasdaq Stockholm

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AroCell AB

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm 17:00:00 20/10/2026 BST			5-day change	1st Jan Change
0.3480 ^SEK	-1.97%		-0.57%	-1.42%

08-20	IDL Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW

Market Cap	81.78M 8.26M 7.35M 6.82M 6.18M 11.61M 783M 11.8M 32.13M 410M 30.99M 30.35M 1.31B	P/E 2024	-2.12x	P/E 2025	-6.69x
Enterprise Value	58.44M 5.9M 5.26M 4.87M 4.41M 8.29M 559M 8.43M 22.96M 293M 22.15M 21.69M 934M	EV / Sales 2024	0.73x	EV / Sales 2025	1.09x
Free-Float	68.85%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	IDLDX	Delayed
Deutsche Boerse AG	80R	Delayed

08-20	IDL Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW
05-27	Calendar Thursday May 28	FW
05-19	IDL Diagnostics Appoints New CEO	MT
05-19	IDL Diagnostics appoints Gustav Sten as CEO	RE
05-19	IDL Diagnostics AB Appoints Gustav Sten as CEO, Effective May 28, 2026	CI
05-13	IDL Diagnostics Q1 net sales SEK 16.7 million	RE
05-13	IDL Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Agneta Tufvesson Alm Declines Re-Election to the Board of IDL Diagnostics AB	CI
03-19	38 stocks hit new 52-week lows on Stockholm Stock Exchange so far today	FW
03-05	IDL Diagnostics CEO to Leave; Search for Successor Starts	MT
03-05	Anders Hultman to step down as CEO of IDL Diagnostics	RE
03-05	Anders Hultman to Step Down as CEO of IDL Diagnostics AB	CI

AroCell AB Share Price

Stocks

IDLDX

SE0003883990

Biotechnology & Medical Research

Valuation: AroCell AB

Chart: AroCell AB

Latest news: AroCell AB

Press Releases: AroCell AB

Quotes and Performance

Price Extremes

Managers and Directors: AroCell AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

10-07	AroCell : IDL Diagnostics at Urology Week in Växjö	PU
09-18	AroCell : Strengthening Healthcare Partnerships at SISP Indonesia 2026	PU
08-21	AroCell : IDL Diagnostics attended Diplomatic Reception hosted by the Embassy of Indonesia	PU
08-21	AroCell : Presentation of IDL Diagnostics Interim Report Q2 2026	PU
08-20	IDL Diagnostics (publ) Interim Report April 1 – June 30, 2026	AQ

1 day	-1.97%
1 week	-0.57%
Current month	-7.45%
1 month	-6.95%
3 months	-16.14%
6 months	-10.08%
Current year	-1.42%

1 week	0.26	0.38
1 month	0.26	0.4
Current year	0.25	0.53
1 year	0.25	0.53
3 years	0.25	0.66
5 years	0.25	2.4
10 years	0.25	8.16

Manager	Title	Age	Since
Gustav Sten CEO	Chief Executive Officer	-	27/05/2026
Ellen Dittberner DFI	Director of Finance/CFO	-	17/08/2022
Leyla Ali Dholey CTO	Chief Tech/Sci/R&D Officer	-	31/12/2024

Director	Title	Age	Since
Eva Nordström BRD	Director/Board Member	56	31/12/2019
Max Pihlqvist CHM	Chairman	39	21/05/2024
Clas Runnberg BRD	Director/Board Member	74	31/12/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/09/21	Michael Brobjer	Buy	Executive/Senior Manager	25,000	0.0220%
02/09/21	Alf Malmberg	Buy		20,000	0.0176%
01/09/21	Eva Nordström	Buy	Director	5,353	0.0047%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AROCELL AB	-1.97%	-0.57%	-6.45%	-30.68%	8.26M
WUXI APPTEC CO., LTD.	+0.79%	-6.46%	+52.86%	+71.34%	65.83B
LONZA GROUP AG	+1.92%	+10.35%	+13.02%	+87.74%	51.87B
ARGENX SE	+6.91%	+8.57%	+6.88%	+72.12%	51.2B
IQVIA HOLDINGS INC.	+1.12%	+2.69%	+26.24%	+45.20%	43.76B
BEONE MEDICINES AG	+3.25%	+9.46%	+19.94%	+131.29%	42.09B
REVOLUTION MEDICINES, INC.	+7.92%	+3.61%	+261.49%	+598.03%	39.04B
CELLTRION, INC.	-0.40%	+9.42%	+18.44%	+59.06%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-4.94%	+42.35%	+8.92%	25.2B
GENMAB A/S	+2.36%	+5.34%	+30.98%	+26.07%	22.8B
Average	+2.59%	+0.32%	+46.57%	+106.91%	37.58B
Weighted average by Cap.	+3.05%	+0.62%	+50.83%	+124.05%

	2024	2025
Net sales	57.44M 5.8M 5.16M 4.79M 4.34M 8.15M 550M 8.29M 22.56M 288M 21.77M 21.31M 918M	53.11M 5.37M 4.78M 4.43M 4.01M 7.54M 508M 7.66M 20.86M 266M 20.12M 19.71M 849M
Net income	-42.45M -4.29M -3.82M -3.54M -3.21M -6.02M -406M -6.13M -16.68M -213M -16.09M -15.75M -678M	-12.15M -1.23M -1.09M -1.01M -918K -1.72M -116M -1.75M -4.77M -60.86M -4.6M -4.51M -194M
Net Debt	-47.78M -4.83M -4.3M -3.98M -3.61M -6.78M -457M -6.9M -18.77M -239M -18.11M -17.73M -763M	-23.34M -2.36M -2.1M -1.94M -1.76M -3.31M -223M -3.37M -9.17M -117M -8.84M -8.66M -373M